Contraception
Volume 81, Issue 5 , Pages 401-407, May 2010

Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation “pill scare”☆☆☆

Berlin Center for Epidemiology and Health Research, 10115 Berlin, Germany

Received 8 September 2009; received in revised form 16 December 2009; accepted 16 December 2009. published online 28 January 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Competing interest: This study was sponsored by an unconditional grant from Bayer Schering Pharma, a leading manufacturer of oral contraceptives, including those containing gestodene.

☆☆ Authors' contributions: L.A.J.H. was responsible for the design of the study, prepared the data analysis plan, ran the analyses and drafted the manuscript; JCD contributed to writing and revising the manuscript and was involved in the data analysis; A.A. was responsible for the development of all questionnaires, contributed to organizing the field work and quality checks, and contributed to the manuscript; T.D.M. was responsible for final data management, involved in the data analyses and contributed to the manuscript.

PII: S0010-7824(09)00540-X

doi:10.1016/j.contraception.2009.12.014

Contraception
Volume 81, Issue 5 , Pages 401-407, May 2010

Article Tools